Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
We tested every peptide tracker app in 2026. Here's what we found, including where our competitors beat us.
The peptide tracker market went from empty to 15+ apps in 12 months. We tested them all and scored them on what matters: safety features, PK modelling, multi-compound support, and price. Pinned is ours. We're transparent about that.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
35+
Articles
18
Categories
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
You're spending $200–500/month on biological software and tracking it in a Notes app. The compounds aren't the problem. The total absence of protocol discipline is.
Peptide access exploded in 2026. Protocol discipline didn't follow. Most users are dosing from Reddit consensus, ignoring half-lives, missing timing windows, and running zero safety baselines. This article maps the specific failure modes, the insulin trap, the NO floor, the receptor ceiling, the sedentary trap, and what precision tracking actually looks like by comparison.
Two sister peptides from the same Cold War lab, one calms the emotional floor, the other raises the cognitive ceiling. The mechanistic case for stacking them is architecturally compelling. The clinical evidence for the combination doesn't exist yet.
Selank and Semax are sister heptapeptides engineered with the same glyproline stability tail but from opposite parent molecules, tuftsin (immune) and ACTH (stress). They converge on BDNF through completely different upstream pathways, covering complementary neurochemical territory. This article examines the mechanistic case for combining them, the cofactors that determine whether either signal lands, and where the evidence stops short.
The peptide revolution promises to rewire your brain — but your immune system might have other plans.
An evidence-based exploration of neuroprotective peptides including GLP-1 receptor agonists, Selank, and Dihexa. We examine clinical promise alongside immunogenicity risks, grey-market purity concerns, and the thin line between neuroregeneration and oncogenic overstimulation.
A four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
Epitalon (AEDG) is a synthetic tetrapeptide modeled after the bovine pineal extract Epithalamin. It upregulates hTERT to activate telomerase, remodels heterochromatin to re-access silenced genes, restores endogenous melatonin production (160% increase in clinical trials), and demonstrated a 28% decrease in overall mortality over a 12-year human follow-up. A 2025 study revealed selective ALT pathway activation in cancer cells. The compound remains investigational — nearly all positive data originates from a single institutional network in St. Petersburg, and independent Western replication is virtually absent.
The biochemical cofactors your body needs to support GHK-Cu therapy.
Evidence-based supplement companion for GHK-Cu : a naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
Two routes, one molecule: how undecanoate rewrote the oral testosterone playbook and what the TRAVERSE trial actually proved about heart safety.
Testosterone undecanoate is the only ester available as both a long-acting injectable (Aveed, Nebido) and a twice-daily oral (Jatenzo, Kyzatrex). Its lymphatic absorption bypasses the liver entirely, solving the hepatotoxicity problem that killed earlier oral steroids. The TRAVERSE trial confirmed cardiovascular non-inferiority, but flagged atrial fibrillation and kidney injury signals that demand ongoing monitoring.
The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.
Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.
Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester in the US, with an 8-day half-life that makes it the backbone of modern TRT. What the clinical data actually says about how to use it.
Evidence-graded profile of testosterone cypionate: pharmacokinetics, subcutaneous vs intramuscular data, the TRAVERSE trial's cardiovascular findings, age-stratified risk, and where peptides fit alongside.